|
|
Eldepryl (Selegiline HCI)
|
 |
Central nervous system agent
|
 |
Antiparkinson agent
|
 |
Parkinson disease. Used as an adjunct to levodopa'carbidopa. Effectiveness of use as sole treatment has not been demonstratated.
|
 |
(Adults) 10 mg/day, administered in divided doses of 5 mg at breakfast and lunch.
|
 |
Category C
|
 |
Nausea, dizziness, abdominal pain, confusion, hallucinations, dry mouth, vivid dreams, headache.
Contraindication: Concomitant use with meperidine or other opioids.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
